---
title: "Cardiovascular Medications"
tags: [medications, cardiovascular, antihypertensives]
sidebar: ccms_medications_sidebar
permalink: /medications/cardiovascular-medications.html
summary: Comprehensive reference for cardiovascular medications including dosing, interactions, and monitoring
---

# Cardiovascular Medications

Comprehensive medication reference for cardiovascular disease management including dosing, contraindications, and monitoring parameters.

## Antihypertensive Agents

### ACE Inhibitors
**Mechanism**: Block conversion of angiotensin I to angiotensin II

| Medication | Starting Dose | Max Dose | Monitoring |
|------------|---------------|----------|------------|
| Lisinopril | 10mg daily | 40mg daily | K+, Cr, BP |
| Enalapril | 5mg BID | 40mg daily | K+, Cr, BP |
| Ramipril | 2.5mg daily | 10mg daily | K+, Cr, BP |

**Contraindications**: Pregnancy, bilateral renal artery stenosis, angioedema history
**Side Effects**: Dry cough, hyperkalemia, renal dysfunction

### Angiotensin Receptor Blockers (ARBs)
**Mechanism**: Block angiotensin II receptors

| Medication | Starting Dose | Max Dose | Monitoring |
|------------|---------------|----------|------------|
| Losartan | 50mg daily | 100mg daily | K+, Cr, BP |
| Valsartan | 80mg daily | 320mg daily | K+, Cr, BP |
| Candesartan | 8mg daily | 32mg daily | K+, Cr, BP |

**Advantages**: No cough, better tolerated than ACE inhibitors
**Contraindications**: Pregnancy, bilateral renal artery stenosis

### Beta-Blockers
**Mechanism**: Block beta-adrenergic receptors

| Medication | Starting Dose | Max Dose | Indications |
|------------|---------------|----------|-------------|
| Metoprolol | 25mg BID | 200mg BID | HTN, MI, HF |
| Carvedilol | 3.125mg BID | 25mg BID | HF, HTN |
| Atenolol | 25mg daily | 100mg daily | HTN, angina |

**Contraindications**: Severe asthma, severe bradycardia, heart block
**Side Effects**: Fatigue, bradycardia, bronchospasm

## Lipid-Lowering Agents

### Statins
**Mechanism**: HMG-CoA reductase inhibition

| Medication | Starting Dose | Max Dose | LDL Reduction |
|------------|---------------|----------|---------------|
| Atorvastatin | 10mg daily | 80mg daily | 50-60% |
| Simvastatin | 20mg daily | 80mg daily | 35-45% |
| Rosuvastatin | 5mg daily | 40mg daily | 50-60% |

**Monitoring**: LFTs, CK, HbA1c
**Side Effects**: Myalgia, hepatotoxicity, diabetes risk

### PCSK9 Inhibitors
**Mechanism**: Block PCSK9 protein, increase LDL receptor recycling

| Medication | Dose | Frequency | Indications |
|------------|------|-----------|-------------|
| Alirocumab | 75-150mg | Q2W | High CV risk |
| Evolocumab | 140mg | Q2W | High CV risk |

**Advantages**: Potent LDL reduction, well-tolerated
**Cost**: High cost, prior authorization required

## Antiplatelet Agents

### Aspirin
- **Dose**: 75-100mg daily for primary prevention
- **Dose**: 325mg loading, then 75-100mg daily for ACS
- **Mechanism**: Irreversible COX-1 inhibition
- **Contraindications**: Active bleeding, severe allergy

### P2Y12 Inhibitors
| Medication | Loading Dose | Maintenance | Duration |
|------------|--------------|-------------|----------|
| Clopidogrel | 600mg | 75mg daily | 12 months |
| Prasugrel | 60mg | 10mg daily | 12 months |
| Ticagrelor | 180mg | 90mg BID | 12 months |

**Monitoring**: Bleeding risk, platelet function
**Drug Interactions**: CYP2C19 inhibitors affect clopidogrel

## Anticoagulants

### Warfarin
- **Dose**: 2-10mg daily (individualized)
- **Target INR**: 2.0-3.0 (most indications)
- **Monitoring**: INR every 1-4 weeks
- **Reversal**: Vitamin K, FFP, PCC

### Direct Oral Anticoagulants (DOACs)
| Medication | Dose | Indication | Monitoring |
|------------|------|------------|------------|
| Apixaban | 5mg BID | AFib, VTE | CrCl |
| Rivaroxaban | 20mg daily | AFib, VTE | CrCl |
| Dabigatran | 150mg BID | AFib, VTE | CrCl |

**Advantages**: No INR monitoring, fewer drug interactions
**Reversal**: Idarucizumab (dabigatran), Andexanet (apixaban/rivaroxaban)

## Drug Interactions

### Major Interactions
- **Warfarin + Aspirin**: Increased bleeding risk
- **Statins + Fibrates**: Increased myopathy risk
- **ACE-I + K+ supplements**: Hyperkalemia risk
- **Beta-blockers + Verapamil**: Bradycardia risk

### Monitoring Requirements
- **Baseline**: CBC, CMP, lipid panel
- **Follow-up**: LFTs (statins), INR (warfarin), K+ (ACE-I/ARBs)
- **Frequency**: Every 3-6 months for stable patients
